Compare MDBH & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | LITS |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 25.7M |
| IPO Year | 2022 | N/A |
| Metric | MDBH | LITS |
|---|---|---|
| Price | $3.32 | $0.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.0K | ★ 357.1K |
| Earning Date | 05-14-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $0.69 |
| 52 Week High | $4.98 | $3.03 |
| Indicator | MDBH | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 53.44 |
| Support Level | $3.16 | $0.79 |
| Resistance Level | $3.83 | $0.99 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 79.74 | 75.81 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.